Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes.
Many patients with bone marrow failure syndromes need frequent transfusions of red blood cells, and most of them eventually suffer from organ dysfunction induced by excessively accumulated iron. The only way to treat transfusion-induced iron overload is iron chelating therapy. However, most patients have not been treated effectively because daily/continuous administration of deferoxamine is difficult for outpatients. Recently, a novel oral iron chelator, deferasirox, has been developed, and introduction of the drug may help many patients benefit from iron chelation therapy. In this review, we will discuss the current status of iron overload in transfusion-dependent patients, and the development of Japanese guidelines for the treatment of iron overload in Japan, which were established by the National Research Group on Idiopathic Bone Marrow Failure Syndromes in Japan.
Suzuki
Takahiro
T
Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0498, Japan.
Tomonaga
Masao
M
Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Miyazaki
Yasushi
Y
Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Nakao
Shinji
S
Department of Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Ohyashiki
Kazuma
K
First Department of Internal Medicine (Department of Hematology), Tokyo Medical University, Tokyo, Japan.
Matsumura
Itaru
I
Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Kohgo
Yutaka
Y
Department of Medicine, Division of Gastroenterology and Hematology/Oncology, Asahikawa Medical College, Asahikawa, Japan.
Niitsu
Yoshiro
Y
Fourth Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
Kojima
Seiji
S
Department of Paediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Ozawa
Keiya
K
Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0498, Japan. kozawa@ms2.jichi.ac.jp.
D044466:Asian People; D001565:Benzoates / Q000627:therapeutic use*; D001855:Bone Marrow Diseases / Q000150:complications / Q000453:epidemiology / Q000628:therapy*; D003625:Data Collection; D000077588:Deferasirox; D017707:Erythrocyte Transfusion / Q000009:adverse effects; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D019190:Iron Overload / Q000188:drug therapy* / Q000453:epidemiology* / Q000209:etiology; D007564:Japan; D017410:Practice Guidelines as Topic; D013577:Syndrome; D014230:Triazoles / Q000627:therapeutic use*
D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox